editor@jprims.in
9343055451
e-ISSN: 3049-1681
logo

Journal of Pharmaceutical Research and Integrated Medical Sciences

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

Volume 3, Issue 4 - 2026 (JPRIMS, Vol-3, Issue-04, April.-2026)

Volume 3 Issue 4 Cover

Issue Details:

Volume 3 Issue 4
Published:Invalid Date

Editorial: JPRIMS, Vol-3, Issue-04, April.-2026

Welcome to the 2026 issue of Journal of Pharmaceutical Research and Integrated Medical Sciences. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Arpan Kumar Tripathi
Editor-in-Chief
Journal of Pharmaceutical Research and Integrated Medical Sciences

Articles in This Issue

Showing 7 of 7 articles
Research PaperID: jprims-00000236

Hallmarks of Aging 2.0: Decoding the Molecular Drivers of Human Longevity – Senolytics Vs. Senomorphics as Strategies to Eliminate Senescent “Zombie” Cells

Yash Srivastav Srivastav, Anubha Dhuriya Dhuriya

The process of aging is a complicated biological phenomenon that is marked by a loss of functionalities and high susceptibility to illness. Recent developments in geroscience have narrowed down the classical paradigm of aging processes into the so-called Hallmarks of Aging 2.0 where molecular pathways including genomic instability, epigenetic changes, mitochondrial dysfunction, chronic inflammation, and cellular senescence are connected. The buildup of senescent cells also known as the zombie cells has come out as one of the major causes of tissue degeneration during the aging process. These cells are metabolically active and irreversibly differentiate but continue to secrete pro-inflammatory factors referred to as senescence-associated secretory phenotype (SASP). There are two key therapeutic approaches that have been optimized to combat cellular senescence; senolytics, which are specific to eliminate senescent cells, and senomorphics, which inhibit the pathogenic secretory phenotype of senescent cells, but do not kill them. The current review presents an overview of the current results of animal-based experimental research on the molecular hallmark of aging and compares the relative efficacy of senolytic and senomorphic treatment in regulating aging pathways. The article identifies the most important experimental models, mechanisms of action, therapeutic potential and limitations of the existing approaches. The knowledge of these strategies offers an insightful critical view of longevity science and can lead to new possibilities in creating anti-aging interventions to work on basic biological processes.

Hplc Water.0.1%OPAValidationMethanolPirfenidone
14,185 views
4,321 downloads

Contributors:

 Yash Srivastav Srivastav
,
 Anubha Dhuriya Dhuriya
Research PaperID: jprims-00000237

The Modern Landscape of Hernia Disease Repair: From Anatomy to Advanced Robotics – A Systematic Review of Animal-Based Clinical Outcomes and Recurrence

Stuti Verma Verma, Yash Srivastav Shrivastava, Vasu Tiwari Tiwari, Neha Rawat Rawat, Anup Kumar Sirbaiya Sirbaiya

The modern repair of hernia disease has undergone tremendous transitions in the past where open surgeries are still used to repair the hernia, to sophisticated minimally invasive and robotic assisted techniques through animal-based research being very essential in the understanding of the structure of the anatomy, biomaterials functions and the healing process. This review is a systematic analysis of the existing literature performed on animal models like rodents, rabbits, pigs, and canines to indicate the efficacy of various types of mesh, surgical methods and new technologies in enhancing clinical outcomes and recurrence. The results suggest that, biologic and composite mesh stimulates tissue integration, neovascularisation and organized collagen deposition and less inflammatory response and adhesion formation in comparison with synthetic mesh. As well, less invasive and robotic-assisted surgery methods enhance surgical accuracy, less tissue trauma, and outcome reproducibility. Nevertheless, interspecies variability, absence of standardized models, and inadequate long-term data are also limitations to direct translational applicability. The review notes the significance of the incorporation of advanced technologies including bioengineered meshes, artificial intelligence, and 3D bio printing and the necessity of standardized and long-term and interdisciplinary research to enhance the safety and efficacy of hernia repair approaches

AgingHallmarks of Aging 2.0SenolyticsSenomorphicsSenescence-Associated Secretory Phenotype (SASP)Longevity+1 more
14,281 views
4,339 downloads

Contributors:

 Stuti Verma Verma
,
 Yash Srivastav Shrivastava
,
 Vasu Tiwari Tiwari
,
 Neha Rawat Rawat
,
 Anup Kumar Sirbaiya Sirbaiya
Research PaperID: jprims-00000238

Advances in Lipid Nanoparticle-Based Oral Drug Delivery: Overcoming Bioavailability and Gastrointestinal Barriers

Richa Srivastava Srivastava

Due to patient compliance and ease, oral drug delivery is the most often used therapeutic administration technique. However, low permeability, enzymatic breakdown, and poor water solubility limit the bioavailability of many medications. Lipid solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), two types of nanoparticles (LNPs), have become potential delivery systems. for enhancing oral drug absorption. This review highlights the classification, functional mechanisms, and formulation factors affecting LNP-based drug delivery systems. This review discusses recent strategies, such as lymphatic transport enhancement, permeability modulation, and drug encapsulation methods. The applications of LNPs in delivering anticancer, antidiabetic, antiviral, and nutraceutical agents are also addressed. Despite regulatory and technical hurdles, continued research and innovation in lipid-based systems have the potential to revolutionize oral drug delivery.

Biomaterials.RecurrenceTissue IntegrationRobotic SurgeryComposite MeshBiologic Mesh+2 more
14,149 views
4,236 downloads

Contributors:

 Richa Srivastava Srivastava
Research PaperID: jprims-00000239

Silver Nanoparticles in Oral Squamous Cell Carcinoma Therapy: A Systematic Review of Preclinical Evidence

Sumit Bhatt Bhatt, Reeva Randeri Randeri, Sai Sagar Sagar, Kishor Patil Patil

Oral squamous cell carcinoma (OSCC) constitutes a significant global health challenge, particularly in low- and middle-income countries, where late-stage diagnoses and therapeutic resistance are prevalent. Conventional treatments, including surgery, chemotherapy, and radiotherapy, are constrained by substantial toxicity, disfigurement, and the emergence of drug resistance. This systematic review evaluates the therapeutic potential of silver nanoparticles (AgNPs) in oral cancer therapy by analyzing 42 preclinical studies published between 2013 and 2025. AgNPs demonstrate multifaceted anticancer activity through polypharmacological mechanisms such as reactive oxygen species (ROS) generation, mitochondrial disruption, DNA damage, and induction of apoptosis via both intrinsic and extrinsic pathways. Additional effects include anti-angiogenic, anti-metastatic, and immunomodulatory properties. AgNPs exhibit selective cytotoxicity toward cancer cells, which is enhanced by their nanoscale dimensions and targeted surface functionalization with ligands such as folic acid. Green synthesis methods provide cost-effective and biocompatible alternatives to conventional chemical synthesis, although issues with batch reproducibility and clinical scalability remain. While in vitro and in vivo studies indicate promising efficacy, concerns persist regarding long-term toxicity, bioaccumulation, and regulatory approval. To date, no AgNP-based formulations have advanced to clinical trials for OSCC. This review highlights critical knowledge gaps and outlines future research priorities to optimize AgNP synthesis, ensure safety, and facilitate clinical translation. AgNPs thus represent a promising multifunctional nanomedicine platform with the potential to advance oral cancer therapeutics through targeted, sustainable, and synergistic strategies.

poorly water-soluble drugsControlled releaseDrug encapsulationLymphatic transportBioavailability enhancementOral drug delivery
14,197 views
4,334 downloads

Contributors:

 Sumit Bhatt Bhatt
,
 Reeva Randeri Randeri
,
 Sai Sagar Sagar
,
 Kishor Patil Patil
Research PaperID: jprims-00000240

Advances in Niosome-Based Drug Delivery Systems for Targeted Dermatological Applications

Sarita Sarita, Anish Menon Menon, Neha Mathur Mathur

Dermatological drug delivery remains a major challenge due to the complex structure and barrier properties of the skin, particularly the stratum corneum, which limits the penetration of therapeutic agents. In recent years, niosomes, non-ionic surfactant-based vesicular systems, have emerged as a promising approach to overcome these limitations. Niosomes possess a unique bilayer structure that allows encapsulation of both hydrophilic and lipophilic drugs, enabling enhanced stability, controlled release, and targeted drug delivery to specific skin layers. Their biocompatibility, cost-effectiveness, and ability to improve drug retention make them superior to conventional systems such as creams, gels, and liposomes. Recent advancements in niosomal technology, including elastic niosomes, proniosomes, and surface-modified formulations, have further improved their performance in dermatological applications such as acne, psoriasis, fungal infections, and inflammatory conditions. Moreover, the integration of nanotechnology and development of hybrid niosome–hydrogel systems have expanded their potential for both therapeutic and cosmetic use. This review highlights the structural characteristics, formulation strategies, mechanisms of skin targeting, and current research trends in niosome-based drug delivery systems, emphasizing their potential to revolutionize topical and transdermal therapies.

Oral squamous cell carcinoma (OSCC)NanomedicineReactive oxygen species (ROS)ApoptosisGreen synthesisTargeted drug delivery+1 more
14,547 views
4,439 downloads

Contributors:

 Sarita Sarita
,
 Anish Menon Menon
,
 Neha Mathur Mathur
Research PaperID: jprims-00000241

Advances in the Management of Cervical Cancer: Surgery, Systemic Therapy, and Immunotherapy

Srikumar Chakravarthi Chakravarthi, Yong Lit Chen Chen, Rajan Rajabalaya Rajabalaya, Barani Karikalan Karikalan, Prarthana Kalerammana Gopalakrishna Gopalakrishna, Mohammad Nazmul Hasan Maziz Maziz

Cervical cancer is a leading global health burden, especially in the context of low- and middle-income countries where screening and vaccination coverage are still low. Although prevention strategies have improved; however, the case for effective treatment modalities remain. Cervical cancer has undergone significant changes in its management since the introduction of multiple therapeutic options over the years. Management of early-stage disease can entail surgical options including conization, hysterectomy, trachelectomy, and pelvic exenteration. Radiotherapy with external beam radiation or brachytherapy remains fundamental to treatment and is frequently administered alongside chemotherapy aimed at improving sensitivity. For locally advanced and metastatic disease, chemotherapy (especially platinum-based regimens) is still the mainstay of treatment, and newer targeted therapies appear effective. In the last few years, immunotherapy has appeared as a revolutionary strategy, among the immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies showed promising results. Moreover, novel targeted therapeutics and combination approaches are being investigated in clinical trials, ushering in an era of personalized medicine for the cervical cancer patient population. Although these advancements lead to improved outcomes for patients, issues related to treatment selection, quality of life, fertility preservation, and access to care continue to be of utmost importance. This review summarizes the status of lock-in treatments in cervical cancer, illustrating both current use and future directions for established and emerging lock-in therapies, with an eye on their real-world clinical implementation and future directions.

Lipid-based carriersProniosomesNanotechnologySkin targetingControlled releaseVesicular systems+2 more
14,583 views
4,490 downloads

Contributors:

 Srikumar Chakravarthi Chakravarthi
,
 Yong Lit Chen Chen
,
 Rajan Rajabalaya Rajabalaya
,
 Barani Karikalan Karikalan
,
 Prarthana Kalerammana Gopalakrishna Gopalakrishna
,
 Mohammad Nazmul Hasan Maziz Maziz
Research PaperID: jprims-00000242

Infant Heart Development, Attachment, and Long-Term Cardiovascular Risk: From Congenital Disease to IoT-Based Predictions

Asfiya Rashid Rashid, Aarushi Pandey Pandey, Pratham Soni Soni, Mohammed Ali Ali, Aman Kumar Singh Singh, Naushad Ali Ali, Farah Deeba Deeba

This review explores the multifaceted relationship among infant heart development, early attachment experiences, and lifelong cardiovascular risks, shaped by genetic, environmental, and technological factors. The primary objective is to synthesise current global research on how congenital heart disease (CHD), parent-infant bonding, and early biological regulation interact to influence long-term cardiac health. Infant cardiac maturation depends on precise genetic programming, but it is susceptible to prenatal conditions, epigenetic modifications, perinatal inflammation, and preterm birth. Beyond structural development, early attachment plays a significant role in modulating stress physiology and autonomic balance, both of which have lasting impacts on cardiovascular function. Secure attachment is increasingly recognised as a protective factor that can buffer the effects of early biological vulnerabilities associated with cardiac disease. At a global level, CHD remains one of the most prevalent congenital anomalies, and advancing neonatal care has transformed survival outcomes. However, this improved survival has highlighted the growing burden of heart failure and other chronic complications later in life. Current clinical trials across continents are examining new biomarkers, early detection techniques, and interventions that target both cardiac repair and developmental adaptation. Parallel to these medical advances, digital health innovations are dramatically reshaping paediatric cardiology. Internet of Things (IoT)-based technologies—such as biosensing wearables, wireless monitors, and cloud-supported data analytics—are creating new possibilities for continuous monitoring and predictive modelling of infant cardiac health. These tools enable early detection of abnormalities, assist in personalised care planning, and may help forecast long-term heart failure risks by integrating physiological, behavioural, and environmental data. This interdisciplinary review calls for closer collaboration among cardiologists, developmental scientists, and data engineers to develop equitable, ethically responsible predictive systems. By linking traditional clinical understanding with emerging digital frameworks, it emphasises a holistic perspective on the prevention and management of cardiovascular disease from infancy through adulthood.

Quality of lifeTreatment strategiesClinical trialsPersonalized medicineTargeted therapyImmunotherapy+4 more
14,587 views
4,374 downloads

Contributors:

 Asfiya Rashid Rashid
,
 Aarushi Pandey Pandey
,
 Pratham Soni Soni
,
 Mohammed Ali Ali
,
 Aman Kumar Singh Singh
,
 Naushad Ali Ali
,
 Farah Deeba Deeba